Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 81 articles: HTML format

Single Articles

June 2026
1. JIN Y, Tian X, Liu W, Guo B, et al
   Noncoding SNP rs17728461 modulates lung cancer progression via interchromosomal regulation of RAB27A expression.
   Oncogene. 2026 Jun 2. doi: 10.1038/s41388-026-03834.
   PubMed     Abstract available
   
   
   May 2026
2. WANG S, Tong X, Sun R, Xia X, et al
   STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4.
   Oncogene. 2026;45:1530-1543.
   PubMed     Abstract available
   
   
   April 2026
3. LYU Q, Liu H, Shen W, Lin Z, et al
   KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway.
   Oncogene. 2026 Apr 29. doi: 10.1038/s41388-026-03798.
   PubMed     Abstract available
   
   
   
4. TANG J, Xu L, Gong Z, Chen L, et al
   USP7-mediated deubiquitination of the KEAP1-NRF2-HMOX1 axis enhances radioresistance in non-small cell lung cancer by suppressing ferroptosis.
   Oncogene. 2026 Apr 23. doi: 10.1038/s41388-026-03783.
   PubMed     Abstract available
   
   
   
5. HEIL BN, Baral G, Pfeffer CM, Bahler MB, et al
   Suppression of PP2A-B56alpha drives EMT in EGFR mutant non-small cell lung cancer.
   Oncogene. 2026 Apr 11. doi: 10.1038/s41388-026-03772.
   PubMed     Abstract available
   
   
   March 2026
6. ZHANG R, Li Y, Lu H, Wang X, et al
   OTUB1/CDYL axis-mediated epigenetic repression of SOX18 facilitates lung cancer progression by inhibiting FDX1-dependent cuproptosis.
   Oncogene. 2026 Mar 30. doi: 10.1038/s41388-026-03748.
   PubMed     Abstract available
   
   
   
7. LAPEYRONNIE E, Granet C, Tricard J, Gallet F, et al
   Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function.
   Oncogene. 2026;45:875-888.
   PubMed     Abstract available
   
   
   
8. LIU Y, Chang Y, Li H, Wang J, et al
   CRTAC1 inhibits progression of lung adenocarcinoma by suppressing integrin/FAK signaling.
   Oncogene. 2026;45:946-960.
   PubMed     Abstract available
   
   
   February 2026
9. WILLIAMS AE, Hoffmann EJ, Inman DR, Gari MK, et al
   Obesity and breast density enhance immune exclusion in the primary tumor microenvironment and promote breast cancer metastasis.
   Oncogene. 2026 Feb 28. doi: 10.1038/s41388-026-03718.
   PubMed     Abstract available
   
   
   
10. LI X, Liu S, Wang R, Wang X, et al
    Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer.
    Oncogene. 2026 Feb 11. doi: 10.1038/s41388-026-03679.
    PubMed     Abstract available
    
    
    
11. REN YZ, Zhao MN, Du FL, Wu L, et al
    POM121 O-GlcNAcylation facilitates bone metastasis in non-small cell lung cancer through enhanced c-MYC nuclear import and ECM reprogramming.
    Oncogene. 2026 Feb 2. doi: 10.1038/s41388-026-03687.
    PubMed     Abstract available
    
    
    
12. LI H, Wu J, Dai H, Li J, et al
    PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation.
    Oncogene. 2026;45:577-590.
    PubMed     Abstract available
    
    
    
13. VAN GENUGTEN JHLT, Fennell DA, Baas P
    BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities.
    Oncogene. 2026;45:593-602.
    PubMed     Abstract available
    
    
    January 2026
14. WANG W, He Q, Fan T, Xiong Y, et al
    An H4K12la/CEBPB-AKR1C2 signaling axis modulates the mTOR pathway to regulate cisplatin resistance in lung cancer.
    Oncogene. 2026 Jan 7. doi: 10.1038/s41388-025-03669.
    PubMed     Abstract available
    
    
    December 2025
15. LUO J, Xu X, Chen Y, Huang Y, et al
    YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis.
    Oncogene. 2025 Dec 16. doi: 10.1038/s41388-025-03660.
    PubMed     Abstract available
    
    
    
16. OGUNLUSI O, Sarkar M, Carter K, Chakrabarti A, et al
    LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway.
    Oncogene. 2025;44:4491-4504.
    PubMed     Abstract available
    
    
    November 2025
17. LIU T, Zuo X, Sun S, Du K, et al
    Overexpressed PRR11-SKA2-miR301a/454 bidirectional transcription unit essentially and coordinately promotes PI3K-AKT pathway activation and lung cancer progression.
    Oncogene. 2025 Nov 27. doi: 10.1038/s41388-025-03607.
    PubMed     Abstract available
    
    
    
18. WU Z, Wang M, Dong X, Sun Y, et al
    The deubiquitinase OTUD1 orchestrates cisplatin chemosensitivity of non-small cell lung cancer through destabilizing RAD23B/XPC.
    Oncogene. 2025 Nov 24. doi: 10.1038/s41388-025-03647.
    PubMed     Abstract available
    
    
    
19. REN Y, Ming R, Zuo A, Liu S, et al
    Cancer-associated fibroblasts drive lung adenocarcinoma progression via THBS2-mediated epithelial-mesenchymal transition.
    Oncogene. 2025;44:4284-4297.
    PubMed     Abstract available
    
    
    
20. ZHANG W, Li J, Zhao J, Lu D, et al
    Targeting ZNRF2-mediated SLC3A2 plasma membrane translocation enhances ferroptosis in lung adenocarcinoma.
    Oncogene. 2025;44:4339-4351.
    PubMed     Abstract available
    
    
    October 2025
21. TONG X, O'Kelly J, Xie D, Mori A, et al
    Retraction Note: Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway.
    Oncogene. 2025 Oct 28. doi: 10.1038/s41388-025-03615.
    PubMed    
    
    
    September 2025
22. YANG M, Lu Y, Zheng J, Zhao X, et al
    PRICKLE3-USP9X interaction-mediated DVL2 deubiquitination promotes the progression of non-small cell lung cancer via canonical WNT pathway.
    Oncogene. 2025 Sep 19. doi: 10.1038/s41388-025-03580.
    PubMed     Abstract available
    
    
    
23. PENG J, Zhang Q, Rao X, Allison DB, et al
    PLK1-mediated PDHA1 phosphorylation drives metabolic reprogramming in lung cancer.
    Oncogene. 2025 Sep 16. doi: 10.1038/s41388-025-03571.
    PubMed     Abstract available
    
    
    
24. LIU L, Chen S, Lei Y, Lin Z, et al
    REPS2 attenuates cancer stemness through inhibiting Wnt signaling by autophagy mediated degradation of beta-catenin.
    Oncogene. 2025;44:2942-2955.
    PubMed     Abstract available
    
    
    
25. ZHOU Y, Wang H, Tang S, He Y, et al
    Identification of RAPGEF3 as the therapeutic vulnerability of basal-subtype lung squamous cell carcinoma.
    Oncogene. 2025;44:3142-3148.
    PubMed     Abstract available
    
    
    August 2025
26. LIN L, Chen L, Lin G, Chen X, et al
    Derlin-3 manipulates the endoplasmic reticulum stress and IgG4 secretion of plasma cells in lung adenocarcinoma.
    Oncogene. 2025;44:2620-2633.
    PubMed     Abstract available
    
    
    
27. SHI R, Farnsworth DA, Febres-Aldana CA, Chow JLM, et al
    Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma.
    Oncogene. 2025;44:2831-2849.
    PubMed     Abstract available
    
    
    July 2025
28. CAO K, Wei S, Ma T, Zou X, et al
    RFX2-BNIP3 axis-driven adaptive mitophagy promotes resistance to ACK1-targeted therapy in non-small cell lung cancer.
    Oncogene. 2025 Jul 25. doi: 10.1038/s41388-025-03502.
    PubMed     Abstract available
    
    
    
29. WALLIS N, Gershon T, Shaaby S, Oberman F, et al
    AVJ16 inhibits lung carcinoma by targeting IGF2BP1.
    Oncogene. 2025 Jul 8. doi: 10.1038/s41388-025-03449.
    PubMed     Abstract available
    
    
    
30. TAN X, Wu C, Banerjee P, Wang S, et al
    Dichotomous roles of ACBD3 in NSCLC growth and metastasis.
    Oncogene. 2025;44:2078-2090.
    PubMed     Abstract available
    
    
    
31. TAKUMIDA H, Saito A, Okabe Y, Terasaki Y, et al
    Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ASCL1 and NEUROD1 in small cell lung cancer.
    Oncogene. 2025 Jul 1. doi: 10.1038/s41388-025-03481.
    PubMed     Abstract available
    
    
    
32. OH YT, Chen Z, Wang D, Ramalingam SS, et al
    Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells.
    Oncogene. 2025;44:2315-2327.
    PubMed     Abstract available
    
    
    June 2025
33. LI S, Lin J, Huang L, Hu S, et al
    STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8(+) T cell exhaustion.
    Oncogene. 2025;44:1452-1462.
    PubMed     Abstract available
    
    
    
34. POIRIER A, Utecht T, Villot R, Gelinas Y, et al
    ZNF768 loss amplifies p53 action and reduces lung tumorigenesis in mice.
    Oncogene. 2025;44:1793-1804.
    PubMed     Abstract available
    
    
    May 2025
35. WANG C, Zhang S, Ma B, Fu Y, et al
    Correction: TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression.
    Oncogene. 2025 May 14. doi: 10.1038/s41388-025-03441.
    PubMed    
    
    
    
36. WANG T, Shen Z, Yang L, Zhang X, et al
    The coagulation and tumor system are directly linked through the proteolysis and activation of epidermal growth factor receptor by thrombin.
    Oncogene. 2025;44:1153-1166.
    PubMed     Abstract available
    
    
    
37. ZHANG C, Zhou W, Xu H, Xu J, et al
    Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop.
    Oncogene. 2025;44:1400-1414.
    PubMed     Abstract available
    
    
    April 2025
38. LIU X, Cui Y, Gong J, Yu X, et al
    SETD5 facilitates stemness and represses ferroptosis via m6A-mediating PKM2 stabilization in non-small cell lung cancer.
    Oncogene. 2025 Apr 30. doi: 10.1038/s41388-025-03426.
    PubMed     Abstract available
    
    
    
39. GAO Y, Li B, Jin Y, Cheng J, et al
    Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis.
    Oncogene. 2025 Apr 15. doi: 10.1038/s41388-025-03388.
    PubMed     Abstract available
    
    
    
40. XU X, Wang S, Zhou H, Tan Q, et al
    Transcriptome-wide association study of alternative polyadenylation identifies susceptibility genes in non-small cell lung cancer.
    Oncogene. 2025 Apr 9. doi: 10.1038/s41388-025-03338.
    PubMed     Abstract available
    
    
    March 2025
41. ZHANG S, Tan YQ, Zhang X, Basappa B, et al
    TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma.
    Oncogene. 2025;44:753-768.
    PubMed     Abstract available
    
    
    February 2025
42. LI H, Li Y, Zheng X, Chen F, et al
    RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1.
    Oncogene. 2025;44:307-321.
    PubMed     Abstract available
    
    
    January 2025
43. ZEESHAN S, Dalal B, Arauz RF, Zingone A, et al
    Global profiling of alternative splicing in non-small cell lung cancer reveals novel histological and population differences.
    Oncogene. 2025 Jan 10. doi: 10.1038/s41388-024-03267.
    PubMed     Abstract available
    
    
    
44. TYAGI A, Wu SY, Sharma S, Wu K, et al
    Retraction Note: Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis.
    Oncogene. 2025 Jan 9. doi: 10.1038/s41388-024-03269.
    PubMed    
    
    
    December 2024
45. LEI Y, Zhong C, Zhang J, Zheng Q, et al
    Senescent lung fibroblasts in idiopathic pulmonary fibrosis facilitate non-small cell lung cancer progression by secreting exosomal MMP1.
    Oncogene. 2024 Dec 11. doi: 10.1038/s41388-024-03236.
    PubMed     Abstract available
    
    
    
46. TANG T, Yang T, Xue H, Liu X, et al
    Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03237.
    PubMed     Abstract available
    
    
    
47. CHEN Y, Zhu X, Wang J, Hu J, et al
    MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma.
    Oncogene. 2024;43:3619-3632.
    PubMed     Abstract available
    
    
    November 2024
48. CHEN T, Ashwood LM, Kondrashova O, Strasser A, et al
    Breathing new insights into the role of mutant p53 in lung cancer.
    Oncogene. 2024 Nov 20. doi: 10.1038/s41388-024-03219.
    PubMed     Abstract available
    
    
    
49. NIU Y, Tang Y, Ma F, Zhou X, et al
    Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15.
    Oncogene. 2024 Nov 8. doi: 10.1038/s41388-024-03202.
    PubMed     Abstract available
    
    
    September 2024
50. LAILLER C, Didelot A, Garinet S, Berthou H, et al
    PrP(C) controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up.
    Oncogene. 2024;43:2781-2794.
    PubMed     Abstract available
    
    
    
51. HAN P, Zhang B, Li Y, Gao R, et al
    MiR-183-5p inhibits lung squamous cell carcinoma survival through disrupting hypoxia adaptation mediated by HIF-1alpha/NDUFA4L2 axis.
    Oncogene. 2024;43:2821-2834.
    PubMed     Abstract available
    
    
    August 2024
52. NGUYEN A, Nunez CG, Tran TA, Girard L, et al
    Jumonji histone demethylases are therapeutic targets in small cell lung cancer.
    Oncogene. 2024 Aug 18. doi: 10.1038/s41388-024-03125.
    PubMed     Abstract available
    
    
    
53. CHEN X, Zhou J, Wang Y, Wang X, et al
    PIM1/NF-kappaB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC.
    Oncogene. 2024;43:2517-2530.
    PubMed     Abstract available
    
    
    
54. SHEN NX, Luo MY, Gu WM, Gong M, et al
    GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma.
    Oncogene. 2024;43:2504-2516.
    PubMed     Abstract available
    
    
    July 2024
55. WANG Z, Lei Z, Wang Y, Wang S, et al
    Bone-metastatic lung adenocarcinoma cells bearing CD74-ROS1 fusion interact with macrophages to promote their dissemination.
    Oncogene. 2024;43:2215-2227.
    PubMed     Abstract available
    
    
    June 2024
56. JIN E, Wang S, Chen D, Wang JP, et al
    P4HA2 activates mTOR via hydroxylation and targeting P4HA2-mTOR inhibits lung adenocarcinoma cell growth.
    Oncogene. 2024;43:1813-1823.
    PubMed     Abstract available
    
    
    
57. LI QQ, Guo M, He GH, Xi KH, et al
    VEGF-induced Nrdp1 deficiency in vascular endothelial cells promotes cancer metastasis by degrading vascular basement membrane.
    Oncogene. 2024;43:1836-1851.
    PubMed     Abstract available
    
    
    
58. WANG K, Guo D, Yan T, Sun S, et al
    ZBTB16 inhibits DNA replication and induces cell cycle arrest by targeting WDHD1 transcription in lung adenocarcinoma.
    Oncogene. 2024;43:1796-1810.
    PubMed     Abstract available
    
    
    
59. CHEN L, Zhang L, He H, Shao F, et al
    Ubiquitin-specific protease 54 regulates GLUT1-mediated aerobic glycolysis to inhibit lung adenocarcinoma progression by modifying p53 degradation.
    Oncogene. 2024;43:2025-2037.
    PubMed     Abstract available
    
    
    May 2024
60. DORE S, Ali M, Sorin M, McDowell SAC, et al
    Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
    Oncogene. 2024 May 14. doi: 10.1038/s41388-024-03051.
    PubMed     Abstract available
    
    
    April 2024
61. WANG X, Li X, Niu L, Lv F, et al
    FAK-LINC01089 negative regulatory loop controls chemoresistance and progression of small cell lung cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03027.
    PubMed     Abstract available
    
    
    
62. ZHANG T, Su F, Wang B, Liu L, et al
    Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma.
    Oncogene. 2024;43:1190-1202.
    PubMed     Abstract available
    
    
    March 2024
63. GUO J, Kim D, Gao J, Kurtyka C, et al
    Retraction Note: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer.
    Oncogene. 2024 Mar 5. doi: 10.1038/s41388-024-02993.
    PubMed    
    
    
    
64. XU X, Qiu S, Zeng B, Huang Y, et al
    N(6)-methyladenosine demethyltransferase FTO mediated m(6)A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis.
    Oncogene. 2024 Mar 5. doi: 10.1038/s41388-024-02992.
    PubMed     Abstract available
    
    
    
65. KUMAR V, Yochum ZA, Devadassan P, Huang EH, et al
    TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.
    Oncogene. 2024 Mar 1. doi: 10.1038/s41388-024-02987.
    PubMed     Abstract available
    
    
    
66. MCCLELLAN B, Wilson CN, Brenner AJ, Jolly CA, et al
    Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities.
    Oncogene. 2024;43:1063-1074.
    PubMed     Abstract available
    
    
    
67. HEIM TE, Hankins ML, Belayneh R, Douglas N, et al
    RNA-sequencing predicts a role of androgen receptor and aldehyde dehydrogenase 1A1 in osteosarcoma lung metastases.
    Oncogene. 2024;43:1007-1018.
    PubMed     Abstract available
    
    
    February 2024
68. GAROFALO M, Quintavalle C, Di Leva G, Zanca C, et al
    Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02989.
    PubMed    
    
    
    
69. TURKOWSKI K, Herzberg F, Gunther S, Weigert A, et al
    miR-147b mediated suppression of DUSP8 promotes lung cancer progression.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02969.
    PubMed     Abstract available
    
    
    January 2024
70. ZHANG Y, Liu L, Pei J, Ren Z, et al
    Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
    Oncogene. 2024 Jan 8. doi: 10.1038/s41388-023-02924.
    PubMed     Abstract available
    
    
    
71. OSER MG, MacPherson D, Oliver TG, Sage J, et al
    Genetically-engineered mouse models of small cell lung cancer: the next generation.
    Oncogene. 2024 Jan 8. doi: 10.1038/s41388-023-02929.
    PubMed     Abstract available
    
    
    
72. MA M, Zhuang J, Li H, Mi R, et al
    Low expression of ZFP36L1 in osteosarcoma promotes lung metastasis by inhibiting the SDC4-TGF-beta signaling feedback loop.
    Oncogene. 2024;43:47-60.
    PubMed     Abstract available
    
    
    December 2023
73. WANG L, Li H, Huang A, Zhao Y, et al
    Mutual regulation between TRIM21 and TRIM8 via K48-linked ubiquitination.
    Oncogene. 2023;42:3708-3718.
    PubMed     Abstract available
    
    
    November 2023
74. CHEN W, Wang F, Yu X, Qi J, et al
    LncRNA MIR31HG fosters stemness malignant features of non-small cell lung cancer via H3K4me1- and H3K27Ace-mediated GLI2 expression.
    Oncogene. 2023 Nov 10. doi: 10.1038/s41388-023-02883.
    PubMed     Abstract available
    
    
    
75. KOU F, Wu L, Zheng Y, Yi Y, et al
    HMGB1/SET/HAT1 complex-mediated SASH1 repression drives glycolysis and metastasis in lung adenocarcinoma.
    Oncogene. 2023;42:3407-3421.
    PubMed     Abstract available
    
    
    
76. SUN X, Dai Y, He J, Li H, et al
    D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.
    Oncogene. 2023;42:3503-3513.
    PubMed     Abstract available
    
    
    October 2023
77. BAI Y, Zhou L, Zhang C, Guo M, et al
    Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
    Oncogene. 2023 Oct 20. doi: 10.1038/s41388-023-02866.
    PubMed     Abstract available
    
    
    
78. LIU Y, Zhang T, Deng J, Huang Q, et al
    The cytotoxicity of (gammadelta)T cells in non-small cell lung cancer mediated via coordination of the BCL-2 and AKT pathways.
    Oncogene. 2023 Oct 7. doi: 10.1038/s41388-023-02852.
    PubMed     Abstract available
    
    
    
79. WANG Y, Liu X, Wang M, Wang Y, et al
    UBE3B promotes breast cancer progression by antagonizing HIF-2alpha degradation.
    Oncogene. 2023 Oct 2. doi: 10.1038/s41388-023-02842.
    PubMed     Abstract available
    
    
    
80. CUI P, Li J, Tao H, Li X, et al
    Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis.
    Oncogene. 2023;42:3098-3112.
    PubMed     Abstract available
    
    
    
81. LIU X, Tian F, Cui J, Gong L, et al
    CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells.
    Oncogene. 2023;42:3113-3126.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum